BioCentury
ARTICLE | Company News

Adaptimmune Therapeutics, University of Texas MD Anderson Cancer Center deal

October 10, 2016 7:00 AM UTC

Adaptimmune and MD Anderson partnered to develop T cell receptor (TCR) cancer therapeutics using Adaptimmune’s Specific Peptide Enhanced Affinity Receptor (SPEAR) technology. The partnership will ini...